Sun Pharmaceutical Industries today said it has received US health regulator’s approval to market generic version of Doxil injection, used in treating ovarian cancer in the American market.

The Mumbai-headquartered firm, in a statement, said its subsidiary has received approval from US food and Drug Administration (USFDA), and US food and Drug Administration (USFDA) for its Doxorubicin HCl Liposome Injection.

“This generic Doxorubicin HCl Liposome injection USP, 2 mg/ml is therapeutically equivalent to Doxil Liposome Injection, 2 mg/ml of Janssen Research and Development, LLC,” the company said.

Doxorubicin HCl liposome injection is used to treat patients with ovarian cancer that has progressed or recurred after platinum-based chemotherapy.

Reacting to the development, shares of Sun Pharma were trading at Rs 745.70 on the BSE in afternoon trade, up 3.84 per cent from their previous close.

(This article was published on February 5, 2013)
XThese are links to The Hindu Business Line suggested by Outbrain, which may or may not be relevant to the other content on this page. You can read Outbrain's privacy and cookie policy here.